Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in developing a diverse range of high-quality pharmaceutical products, including innovative prescription medications and over-the-counter solutions.
Cspc operates extensively across major regions, including Asia and Europe, and is recognised for its commitment to research and development, which has led to numerous breakthroughs in therapeutic areas such as oncology and cardiovascular health. With a strong market position, Cspc has garnered accolades for its advanced manufacturing capabilities and adherence to stringent quality standards, solidifying its reputation as a trusted name in the global pharmaceutical landscape.
-11 vs industry average
Cspc Pharmaceutical’s score of 31 is lower than 44% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
CSPC Pharmaceutical Group Limited, a pharmaceutical preparation manufacturer based in HK, reported total Scope 1 emissions of approximately 474,567,040 kg CO2e and Scope 2 emissions of about 493,310,000 kg CO2e in 2024. This marks a decrease from 2023, which saw Scope 1 emissions at approximately 663,224,000 kg CO2e and Scope 2 emissions at about 418,037,000 kg CO2e. The company has not disclosed Scope 3 emissions data for these years.
CSPC Pharmaceutical is committed to reducing its carbon footprint, setting intensity reduction targets for greenhouse gas emissions per unit revenue. For Scope 1 emissions, they aim for a 53% reduction between 2024-2026 (from a 2017 baseline), followed by a 56% reduction for 2027-2028, and a 60% reduction for 2029-2030. Similar targets are in place for Scope 2 emissions, with a 53% reduction aimed for 2024-2026 and a 56% reduction for 2027-2028. The company also states a commitment to referencing the Task Force on Climate-related Financial Disclosures (TCFD) suggestions to identify climate-related risks and opportunities.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more